ScholarIQanswers from OpenAlex & ORCID
Stephen K. Tyring
ResearcherPublications, citations & collaboration network
Stephen K. Tyring is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stephen K. Tyring have?
ScholarIQindexed works
Stephen K. Tyring has 680 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stephen K. Tyring have?
ScholarIQcitation count
Stephen K. Tyring has 25,391 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stephen K. Tyring?
ScholarIQh-index
Stephen K. Tyring has an h-index of 75 in OpenAlex.
What is the i10-index of Stephen K. Tyring?
ScholarIQi10-index
Stephen K. Tyring has an i10-index of 301 in OpenAlex.
What is the ORCID of Stephen K. Tyring?
ScholarIQorcid
The ORCID for Stephen K. Tyring is on the source record.
What is the OpenAlex record for Stephen K. Tyring?
ScholarIQopenalex
The OpenAlex for Stephen K. Tyring is on the source record.
What are the most-cited papers on Stephen K. Tyring?
ScholarIQmost cited works
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich, Kim Papp, Andrew Blauvelt, Stephen K. Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, N. Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B. Kimball
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G. Krueger, J.‐P. Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen K. Tyring, B Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J. Padula
High-Level Variability in the ORF-K1 Membrane Protein Gene at the Left End of the Kaposi’s Sarcoma-Associated Herpesvirus Genome Defines Four Major Virus Subtypes and Multiple Variants or Clades in Different Human Populations
Jian-Chao Zong, D M Ciufo, Donald J. Alcendor, Xiaoyu Wan, John Nicholas, Philip J. Browning, Peter L. Rady, Stephen K. Tyring, Jan M. Orenstein, Charles S. Rabkin, Ih‐Jen Su, K.F.H. Powell, Margaret C. Croxson, Kimberly E. Foreman, Brian J. Nickoloff, Serhan Alkan, Gary S. Hayward